Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Total Assets Chart for Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) total assets for FY2025 were USD 3.7B, a 5.1% change from FY2024. Amneal Pharmaceuticals, Inc. Class A Common Stock's total assets grew from USD 1.9B in 2014 to USD 3.7B in 2025 (91.3% over 11 years). Total assets compound annual growth rate: 5-year CAGR of -1.7%, 10-year CAGR of 13.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $7.10B
- Implied Share Price
- $20.38
- Enterprise Value
- $5.78B
- Revenue (TTM)
- $3.12B
- EBITDA
- $689.44M
- Profit Margin
- 5.05%
- Trailing P/E
- 41.59
- Forward P/E
- 6.30
- Price/Book (MRQ)
- 203.97
- Price/Sales (TTM)
- 2.28
- EV/EBITDA
- 9.89
- EV/Revenue
- 2.02
- Dividend Yield
- —
- Book Value
- $0.10
- Free Cash Flow (FY2025)
- $269.93M
- Free Cash Flow Yield
- 3.80%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.